Evidence mapPaperPMID 38007662Full record

ArticleJournal of Alzheimer's disease : JAD2023

Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer's Disease in the HABS-HD Study.

Fan Zhang, Melissa Petersen, Leigh Johnson, James Hall, Sid E O'Bryant, Health and Aging Brain Study (HABS-HD) Study Team

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Precision medicine for Alzheimer's disease in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fan ZhangInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Melissa PetersenInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Leigh JohnsonInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
James HallInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Sid E O'BryantInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Health and Aging Brain Study (HABS-HD) Study Team

Funding

The Health & Aging Brain Study - Health Disparities (HABS-HD)U19AG078109 · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2025 to 2025
$31.8M
Health and Aging Brain among Latino Elders (HABLE-AT(N)) StudyR01AG058533 · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2025 to 2025
$8.9M
NIA NIH HHS R01 AG054073NIA NIH HHS R01 AG058533NIA NIH HHS R01 AG058537NIA NIH HHS U19 AG078109NIBIB NIH HHS P41 EB015922
6 · The paper itself

Abstract

backgroundBlood biomarkers have the potential to transform Alzheimer's disease (AD) diagnosis and monitoring, yet their integration with common medical comorbidities remains insufficiently explored.

objectiveThis study aims to enhance blood biomarkers' sensitivity, specificity, and predictive performance by incorporating comorbidities. We assess this integration's efficacy in diagnostic classification using machine learning, hypothesizing that it can identify a confident set of predictive features.

methodsWe analyzed data from 1,705 participants in the Health and Aging Brain Study-Health Disparities, including 116 AD patients, 261 with mild cognitive impairment, and 1,328 cognitively normal controls. Blood samples were assayed using electrochemiluminescence and single molecule array technology, alongside comorbidity data gathered through clinical interviews and medical records. We visually explored blood biomarker and comorbidity characteristics, developed a Feature Importance and SVM-based Leave-One-Out Recursive Feature Elimination (FI-SVM-RFE-LOO) method to optimize feature selection, and compared four models: Biomarker Only, Comorbidity Only, Biomarker and Comorbidity, and Feature-Selected Biomarker and Comorbidity.

resultsThe combination model incorporating 17 blood biomarkers and 12 comorbidity variables outperformed single-modal models, with NPV12 at 92.78%, AUC at 67.59%, and Sensitivity at 65.70%. Feature selection led to 22 chosen features, resulting in the highest performance, with NPV12 at 93.76%, AUC at 69.22%, and Sensitivity at 70.69%. Additionally, interpretative machine learning highlighted factors contributing to improved prediction performance.

conclusionsIn conclusion, combining feature-selected biomarkers and comorbidities enhances prediction performance, while feature selection optimizes their integration. These findings hold promise for understanding AD pathophysiology and advancing preventive treatments.

Indexed as

Alzheimer DiseaseCognitive DysfunctionBiomarkersBrainComorbidityHumansBiomarkersAlzheimer’s diseaseblood biomarkerscomorbiditiesmachine learningrecursive feature eliminationsupport vector machine

Identifiers

PMID38007662
PMCPMC13386654

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.